Moderna loses bid to invalidate Arbutus patent

Biotech company Moderna has failed to have a US patent owned by its competitor Arbutus Biopharma revoked, following a decision handed down by the Patent Trial and Appeal Board (PTAB) yesterday, July 23.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Americas

Moderna’s COVID-19 and Zika patent applications to be investigated

8 September 2020 A US Department of Health and Human Services agency will investigate whether Moderna disclosed information on government funding in patent applications relating to its COVID-19 vaccine.

Americas

Moderna unsure of COVID-19 vaccine patent exclusivity

12 August 2020 US biotech company Moderna has said it’s possible that it may not be the first company to make the inventions claimed in its pending patent applications, which include the breakthroughs for its experimental COVID-19 vaccine.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Moderna loses bid to invalidate Arbutus patent

More on this story

Editor's picks

Editor's picks

More features